Hiromachi, Japan

Kazue Hasegawa

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Sankyo Company, Limited. Active years: 1986.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kazue Hasegawa. Retrieved from https://idiyas.com/inventor/kazue-hasegawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 21(Granted Patents)


Company Filing History:


Years Active: 1986

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kazue Hasegawa: Innovator in Ophthalmic Anti-Inflammatory Agents

Introduction

Kazue Hasegawa is a prominent inventor based in Hiromachi, Japan. She has made significant contributions to the field of ophthalmology through her innovative research and development of anti-inflammatory agents.

Latest Patents

Hasegawa holds a patent for ophthalmic anti-inflammatory agents, specifically compounds that include a formula where R represents hydrogen or methyl. The compounds are designed to be effective as ophthalmic anti-inflammatory agents, along with their acceptable salts and esters.

Career Highlights

Kazue Hasegawa is associated with Sankyo Company, Limited, where she has been instrumental in advancing research in ophthalmic treatments. Her work has led to the development of valuable pharmaceutical products that address inflammation in the eye.

Collaborations

Hasegawa has collaborated with notable colleagues, including Masaharu Fukami and Atsusuke Terada, to further enhance the impact of her research in the field.

Conclusion

Kazue Hasegawa's contributions to ophthalmic anti-inflammatory agents highlight her role as an influential inventor in the pharmaceutical industry. Her work continues to pave the way for advancements in eye care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…